top of page

Leadership Team


Suchi Acharya, PhD

Founder and CEO

Dr. Suchismita Acharya is the Founding President of AyuVis Research. Prior to AyuVis, She spent 15 years in various leadership roles with  Alcon Labs (Novartis) and led projects from early stage to pre-clinical in glaucoma, AMD and anti-viral diseases.


She is an innovative scientist with the ambition of adding first in-class small molecules for ocular as well as anti bacterial/viral diseases to AyuVis’ research and drug discovery portfolio. She is a certified Project Manager and managed drug discovery projects from hit to lead, lead optimization and lead the project through phase-I-III clinical trials in humans.



David Riley, MD, MBA

Chief Medical Officer

Dr. David Riley is board certified in pediatrics and neonatal-perinatal medicine at Cook's Children Hospital in Fort Worth, TX.


Dr. Riley received his undergraduate degree in Biochemistry from Cornell University, medical degree from Stanford University School of Medicine, completed his pediatric residency at the University of North Carolina Hospitals, and neonatal-perinatal fellowship at the University of Texas in Houston. His research interests include neonatal immunology and infectious disease, respiratory physiology and evidenced based medicine.



Russell Bromley, BA

Director of Operations

Mr. Russell Bromley brings us 30 years of management experience in life science research and healthcare.

Mr. Bromley has an undergraduate degree in Biochemistry from Rice University. He has experience as a consultant, founder, CEO, COO, and president to biomedical research institutions, foundations and companies in healthcare, IT and high-tech manufacturing, including 17 years with Baxter Healthcare.



Management Team: TeamMember

Dennis Dean, PhD

Head of CMC

Dr. Dennis Dean is an innovative process chemist with 30+ years experience in synthetic organic chemistry, heterocyclic chemistry, process development, route selection, and optimization and process validation. He is experienced in the synthesis of small molecules for medicinal uses such as steroids, prostaglandins, heterocycles, peptides and nucleotides.


In addition, he has extensive experience in CMC and compliance areas as they relate to GMP API manufacturing, in particular APIs for clinical development. This includes regulatory filings and GMP audits of API manufacturers.



Mariam Morris, CPA, MS

Fractional Chief Financial Officer

Ms. Mariam Morris is an effective leader with over 25 years experience in business strategic planning and analysis. She is an ethical professional with extensive experience in the BioPharma industry, SEC reporting, and transaction analysis. She has managed operations, internal infrastructure, and controls design. She also has experience in business development and investor relations.

Mariam's specialty expertise includes extensive understanding of roles and responsibilities required of today's financial executives; SEC, GAAP, IFRS, and Tax; design and implementation of strategic plans for growth for start up and mid-size companies.



Ranjan Misra

Business Advisor

Mr. Ranjan Misra has 30+ years of global business experience with large multinational and privately held companies, including general management, business development, fundraising, client  management and operations.


He has also assisted private equity firms with acquisitions, divestitures, and roll-ups of portfolio companies.



Dale Christensen, PhD

Director of Early Development

Dr. Dale Christensen brings us over 25 years of of R&D VP/CSO  experience from small and big pharmaceutical companies.

Dr. Christensen has an undergraduate degree in Chemistry from the University or Utah and a PhD in Chemistry from Utah State University. He has more than 20 years of experience developing novel therapeutics with an emphasis on IND-enabling toxicology and safety pharmacology studies. He specializes in developing and reviewing study protocols, managing preclinical CROs, analyzing data, and trouble-shooting toxicity, PK, and safety pharmacology studies for preclinical and IND-enabling studies.



bottom of page